Treatment of resistant bacterial infections in children: Thinking inside and outside the box

Advances in Experimental Medicine and Biology

Volumn 764, Issue , 2013, Pages 123-132

  Livni, Gilat ^a   Ashkenazi, Shai ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM DERIVATIVE; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFTAROLINE; CEFTRIAXONE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; LINEZOLID; METICILLIN; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOGRAMIN DERIVATIVE; TEICOPLANIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL GENE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CEREBROSPINAL FLUID; COMMUNICABLE DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENDOCARDITIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOLOGIC DISEASE; HOSPITALIZATION; HUMAN; MECA GENE; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NAUSEA; NECROTIZING FASCIITIS; NONHUMAN; NONMENINGEAL INFECTION; OSTEOMYELITIS; PENICILLIN RESISTANT STREPTOCOCCUS PNEUMONIAE; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RIGHT SIDED ENDOCARDITIS; SKIN ABSCESS; SKIN AND SOFT TISSUE INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTOPENIA; TREATMENT INDICATION; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; VOMITING;

EID: 84873589034     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-4726-9_9     Document Type: Article

References (39)

1. Gupta N, Limbago BM, Patel JB, Kallen AJ (2011) Carbapenem-resistant Enterobacteriaceae: Epidemiology and prevention. Clin Infect Dis 53(1):60-677
2. Perez F, Hujer AM, Hujer KM, Decker BK, Rather ON, Bonomo RA (2007) Global challenge of multidrug resistant Acinetobacter baumani. Antimicrobial Agents Chemother 51(10):3471-34844
3. Paterson DL (2008) Impact of antibiotic resistance in Gram-negative bacilli on empirical and definitive antibiotic therapy. Clin Infect Dis 47(Suppl1):14-200
4. Paterson DL, Rogers BA (2010) How soon is now? The urgent need for randomized controlled trials evaluating treatment for multi-drug resistant bacterial infections. Clin Infect Dis 51(11):1245-12477
5. Sievent DM, Rudrick JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC (2008) Vancomycinresistant Staphylococcus aureus in the Unites States, 2002-2006. Clin Infect Dis 46(5):668-6744
6. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R et al (2010) Emergence of a new antibiotic resistance mechanism in India, Pakistan and the UK: A molecular, biological and epidemiological study. Lancet Infect Dis 10(9):597-6022
7. Chen LF, Chopra T, Kaye KS (2009) Pathogens resistant to antimicrobial agents. Infect Dis Clin North Am 23(4):817-8455
8. Normark BH, Normark S (2002) Evolution and spread of antibiotic resistance. J intern Med 252(2):91-1066
9. Castanheira M, Mendes RE, Woosley LN, Jones RN (2011) Trends in carbapenemase-producing Escherichia coli and Klebsiella app from Europe and the Americas: Report from the SENTRY antimicrobial surveillance programme (2007-09). J Antimicrobial Chemother 66(6):1409-14111
10. Carrillo-Marquez MA, Hulten KG, Hammerman W, Lamberth L, Mason EO, Kaplan SL (2011) Staphylococcus aureus pneumonia in children in the era of community-acquired methicillin-resistance at Texas Children's Hospital. Pediatr Infect Dis J 30(7):545-5500
11. Nordmann P, Poirel L, Toleman MA, Walsh TR (2011) Does broad-spectrum ®-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J Antimicrobial Chemother 66(4):689-6922
12. British Society for Antimicrobial Chemotherapy (2011) The urgent need for new antimicrobial agents. J Antimicrobial Chemother 66(6):1939-19400
13. Dagan R, Greenberg D, Jacobs MR, Phillips BL (2009) Pneumococcal infections. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (eds) Textbook of Pediatric Infectious Diseases, 6th edn. p 1288-13422
14. Hsu KK, Shea KM, Stevenson AE, Pelton SI (2010) Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J 29(4):289-2933
15. Markiewicz Z, Tomasz A (1989) Variations in penicillin-binding protein patterns of penicillin-resistant clinical isolates of pneumococci. J Clin Microbiol 27(3):405-4100
16. Clinical and Laboratory Standards Institute (2011) Performance standards for antimicrobial susceptibility testing (Table 2G), Wayne.\\
17. Martinez-Aguilar G, Hammerman WA, Mason EO, Kaplan SL (2011) Clindamycin treatment of invasive infections caused by community-acquired methicillin-resistant and methicillin-sensitive Staphylococcus aureus in children. Pediatr Infect Dis J 22(7):593-5988
18. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52(3):285-2922
19. Gemmel CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE (2006) Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus infections in the UK. J Antimicrobial Chemother 57(4):589-6088
20. Markwell S, Peter J, Barenkamp S (2010) Randomized controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patients. Ann Emerg Med 55(5):401-4077
21. Peltola H, Paakkonen M, Kallio MJT (2010) Shortversus long-term antimicrobial treatment for acute osteomyelitis of children: Prospective, randomized trial on 131 culture-proven cases. Pediatr Infect Dis J 29(12):1123-11288
22. Garazzino S, Tovo PA (2011) Clinical experience with linezolid in infants and children. J Antimicrobial Chemother 66(Suppl 4):23-411
23. Chavez-Bueno S, Stull TL (2009) Antibacterial agents in children. Infect Dis Clin North Am 23(4):865-8800
24. Ardura MI, Mejias A, Katz KS, Ravell P, McCracken GH, Sanchez PJ (2007) Daptomycin therapy for invasive Gram-positive bacterial infections in children. Pediatr Infect Dis J 26(12):1128-11322
25. The Pediatric Infectious Disease Newsletter (2011) Ceftaroline approved. Pediatr Infect Dis J 30(4):A77
26. Laudano JB (2011) Ceftaroline fosamil: A new broad-spectrum cephalosporin. J Antimicrobial Chemother 66(Suppl 3):11-188
27. Sievent DM, Rudrik JT, Patel JB (2008) Vancomycin-resistant S. aureus in the United States, 2002-2006. Clin Infect Dis 46(5):668-6744
28. Jones RN (2006) Microbiological features of vancomycin in the 21st century: MIC creep, bactericidal/static activity and applied breakpoints to predict outcomes or detect resistant strains. Clin Infect Dis 42(Suppl 1):13-244
29. Holmes NE, Turnidge JD, Munckholf WJ, Robinson JO, Korman TM, O'Sullivan MVN et al (2011) Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 204(3):340-3477
30. Zheng X, Qi C, Arrieta M, O'leary A, Wang D, Shulman ST (2010) Lack of increase in vancomycin resistance of pediatric methicillin-resistant Staphylococcus aureus isolates from 2000 to 2007. Pediatr Infect Dis J 29(9):882-8844
31. Jacoby GA (1997) Extended-spectrum ®-lactamases and other enzymes providing resistance to oxyimino-®-lactams. Infect Dis Clin North Am 11(4):875-8877
32. Hague R (2011) What is the threat from extended spectrum ®-lactamaze-producing organisms in children? Arch Dis Child 96(4):325-3277
33. Tamma PD, Jenh AM, Milstone AM (2011) Prolonged ®-lactam infusion for Gram-negative infections. Pediatr Infect Dis J 30(4):336-3377
34. Overturf GD (2010) Carbapenemnases: A brief review for pediatric infectious disease specialist. Pediatr Infect Dis J 29(1):68-700
35. Bradley JS, Jackson MA, Committee on Infectious Diseases, American Academy of Pediatrics (2011) Clinical report - The use of systemic and topical fluoroquinolones. Pediatrics 128(4):1034-10455
36. Tamma PD, Lee CK (2009) Use of Colistin in children. Pediatr Infect Dis J 28(6):534-5355
37. Jajoo M, Kumar V, Jain M, Kumari S, Manchandra V (2011) Intravenous colistin administration in neonates. Pediatr Infect Dis J 30(3):218-2211
38. Yahav D, Lador A, Paul M, Leibovici L (2011) Efficacy and safety of tigecycline: A systematic review and meta-analysis. J Antimicrob Chemother 66(9):1963-19711
39. Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinowitch B et al (2011) Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 52(7):848-8555